CD47 and non-Hodgkin lymphoma: A phase I/II study with the CD47 antibody magrolimab (hu5F9-G4) in combination with the CD20 antibody rituximab revealed mild toxicities and demonstrated encouraging clinical responses in patients with advanced non-Hodgkin’s lymphomas (13).